Abstract: Compounds of the general formula ##STR1## wherein R.sub.1 is n-propyl or cyclobutyl;R.sub.2 is isopropyl, tertiary butyl, cyclobutyl, cyclopentyl or cyclohexyl;R.sub.3 is hydrogen;R.sub.4 is hydrogen or methyl;as (R)-enantiomer in the form of free base or pharmaceutically acceptable salts thereof, process for their preparation, pharmaceutical composition, use of and method of treatment of disorders in CNS.

Abstract: The machine has a cooled and moving substrate, for example an endless horizontal belt, a feeding device, for example a tundish, and a distributor arranged transversely to the substrate for distributing liquid metal over the substrate. The distributor can have an outlet for permitting a stream of liquid metal to exit the distributor, into a gaseous medium which can be enclosed by a hood or cover, at a substantial angle from the horizontal and vertical axes of the distributor, and the pressure of the liquid metal at the outlet can also be varied.

Abstract: 3-amino-5-carbamoylchromans and 8-fluoro-3-amino-5-carbamoylchromans, as well as enantiomers and salts thereof, are disclosed. Pharmaceutical compositions containing the compounds as active ingredients are also disclosed. The compounds are useful in the treatment of 5-hydroxytryptamine-mediated disorders of the central nervous system.

Abstract: Novel therapeutically active compounds of the formula ##STR1## wherein Z.sup.i, being Z.sup.1, Z.sup.2 or Z.sup.3, is the same or different and selected among OH, OR.sup.1, NH.sub.2, NR.sub.2.sup.4, NHR.sup.4, SH, SR.sup.4 and OR.sup.4 wherein R.sup.1 is a formyl group, an acyl group, an alkoxycarbonyl group or a mono- or dialkylcarbamoyl group and R.sup.4 is a lower alkyl group,R.sup.2 is a hydrogen, a halogen, a lower alkyl or a lower trifluoroalkyl group,R.sup.3 is a hydrogen atom, a lower alkyl group, an alkenyl group, an alkynyl group or a phenyl group, which phenyl group could optionally be substituted by one or more of fluoro, chloro, bromo, trifluoromethyl, methyl, ethyl, methoxy or ethoxy in the ortho, meta or para positions, or optionally substituted by methylenedioxy, provided that at least one of Z.sup.1, Z.sup.2 and Z.sup.3 is a group OR.sup.4 and further provided that when Z.sup.2 is OH or NH.sub.2, Z.sup.1 is NR.sub.2.sup.4, NHR.sup.4, SH, SR.sup.4 or OR.sup.